54.19
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com
What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional
What analysts say about Protagonist Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lancaster Eagle-Gazette
Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus
How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com
How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser
Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser
Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛
Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech
Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com
Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman
Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Insider Monkey
10 Biotech Stocks Screaming a Buy - Insider Monkey
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus
Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus
Citi initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com Nigeria
How To Trade (PTGX) - news.stocktradersdaily.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):